Next Science Limited

Successfully Listed on ASX Post IPO Event: An Australian-based medical technology company, Next Science Limited (ASX: NXS) recently announced that Dr. Matthew Myntti became a substantial holder of the group since April 16, 2019 with voting power of 11.53%.In another update, the company announced that the shareholding update of its Managing Director, Judith Mitchell wherein she holds ~ 2.64% interest of the total outstanding.

On April 18, 2019, the company got listed on ASX with 179,164,575 total shares including current shares, options, and convertible notes on issue with the market capitalization of $179,164,575 at an issue price of $1 per share.


FY18 P&L Statement (Source: Company Reports)

Financials: The company’s total income increased by 419% to US$2.8 million in FY18 on the YoY basis mainly driven by the increased sales of Bactisure and the ramp up of BlastX sales through Next Science direct sales team based in the US.

What To Expect From The Company: The company intends to continue its strategy of sales through established distributors rather than directly market and sell its products itself.It also intends to seek opportunities for technology licencing agreements for the inclusion of Xbio technology in products manufactured by others and strategic agreements with pharmaceutical companies for the delivery of Xbio technology in future pharmaceutical products.

Stock Recommendation: Next Science’s share recently got listed on ASX, and it got closed at $1.675 per share (on April 23, 2019) and was up by 24.074% on intraday basis. However, the company’s stock is trading towards the 52-week higher level and any correction in the near term can offer a good entry opportunity. Hence, we put our wait and watch stance on the stock at the current market price of $1.675 per share.
 

Tinybeans Group Ltd.

143% (pcp) Rise In Top Line growth For Q3FY19: Mobile and Web-based service provider, Tinybeans Group Ltd (ASX: TNY) recently announced March quarter FY2019 performance where it reported increase in revenue by 143% on Q3 FY 2018 to $992,081 in Q3FY19, majorly driven by increase in advertising, subscription, and printing revenue.It reported increase in its registered users from 2.3 Mn at the end of March 2018 to 3.2 Mn in March 2019. As at 31 March 2019, the company had a cash and cash equivalent of $1.455 Mn.

Key Metrics (Source: Company Reports)

What To Expect: It is expected that the cash burn for Q4FY19 would be in between $300k and $400k.The company expects to achieve cash flow breakeven by the end of the calendar year 2019. It also aims to continue to evaluate raising additional capital as the business growth continues.

Stock Recommendation: Tinybeans’ share generated positive YTD return of 90.48%, showing better return to the shareholders over the same period. As on April 23, 2019, the stock’s price was up by 14.167% and has been close to its 52-week high of $0.735. On technical analysis front, the stock is trading in the over-bought region of Relative Strength Index (14 days) which implies that the stock might see some correction in the near future. Based on the foregoing, we advise the market players to keep a watch on the stock at the current market price of A$0.685 per share andwait for corrections for a better entry position. 
 

Disclaimer
 
The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkine.com.au and associated pages are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). The information on this website has been prepared from a wide variety of sources, which Kalkine Pty Ltd, to the best of its knowledge and belief, considers accurate. You should make your own enquiries about any investments and we strongly suggest you seek advice before acting upon any recommendation. Kalkine Pty Ltd has made every effort to ensure the reliability of information contained in its newsletters and websites. All information represents our views at the date of publication and may change without notice. To the extent permitted by law, Kalkine Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services. There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. The link to our Terms & Conditions has been provided please go through them and also have a read of the Financial Services Guide. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.